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Abstract 
We investigated the impact of durvalumab ± tremelimumab versus chemotherapy on patient-reported 
symptoms, functioning, and global health status/quality of life in the phase 3 MYSTIC trial of metastatic non–
small-cell lung cancer in patients with tumor cell programmed cell death ligand 1 expression ≥ 25%. Durval- 
umab ± tremelimumab reduced symptom burden and improved times to deterioration, suggesting there were 
no detrimental effects with treatment. 
Background: The phase 3 MYSTIC study of durvalumab ± tremelimumab versus chemotherapy in metastatic non–
small-cell lung cancer (NSCLC) patients with tumor cell (TC) programmed cell death ligand 1 (PD-L1) expression ≥ 25% 
did not meet its primary endpoints. We report patient-reported outcomes (PROs). Patients and Methods: Treatment- 
naïve patients were randomized (1:1:1) to dur valumab, dur valumab + tremelimumab, or chemotherapy. PROs were 
assessed in patients with PD-L1 TC ≥ 25% using EORTC Quality of Life Questionnaire (QLQ)-C30/LC13. Changes from 
baseline (12 months) for prespecified PRO endpoints of interest were analyzed by mixed model for repeated measures 
(MMRM) and time to deterioration (TTD) by stratified log-rank tests. Results: There were no between-arm differences in 
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baseline PROs ( N = 488). Between-arm differences in MMRM-adjusted mean changes from baseline favored at least 
one of the durvalumab-containing arms versus chemotherapy (nominal P < .01) for C30 fatigue: durvalumab ( −9.5; 
99% confidence interval [CI], −17.0 to −2.0), durvalumab + tremelimumab ( −11.7; 99% CI, −19.4 to −4.1); and for C30 
appetite loss: durvalumab ( −11.9; 99% CI, −21.1 to −2.7). TTD was longer with at least one of the durvalumab-containing 
arms versus chemotherapy (nominal P < .01) for global health status/quality of life: durvalumab (hazard ratio [HR] = 0.7; 
95% CI, 0.5-1.0), durvalumab + tremelimumab (HR = 0.7; 95% CI, 0.5-1.0); and for physical functioning: durvalumab 
(HR = 0.6; 95% CI, 0.4-0.8), durvalumab + tremelimumab (HR = 0.6; 95% CI, 0.5-0.9) (both C30); as well as for the 
key symptoms of dyspnea: durvalumab (HR = 0.6; 95% CI, 0.5-0.9), durvalumab + tremelimumab (HR = 0.7; 95% CI, 
0.5-1.0) (both LC13); fatigue: durvalumab + tremelimumab (HR = 0.6; 95% CI, 0.4-0.8); and appetite loss: durvalumab 
(HR = 0.5; 95% CI, 0.4-0.7), durvalumab + tremelimumab (HR = 0.7; 95% CI, 0.5-0.9) (both C30). Conclusion: Durval- 
umab ± tremelimumab versus chemotherapy reduced symptom burden and improved TTD of PROs, suggesting it had 
no detrimental effects on quality of life in metastatic NSCLC patients. 
Clinical Lung Cancer, Vol. 22, No. 4, 301–312 © 2021 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 

































































Historically, the prognosis for patients with metastatic non–
small-cell lung cancer (NSCLC) has been poor, with 5-year survival
of approximately 6%. 1 However, the introduction of immune
checkpoint inhibitors that target the programmed cell death protein
1 (PD-1) receptor or its ligand (PD-L1) has significantly improved
outcomes, prolonging both overall survival (OS) and progression-
free survival (PFS). Durvalumab is a selective, high-affinity human
immunoglobulin G1 monoclonal antibody that blocks PD-L1
binding to PD-1 and CD80. 2 It is approved globally for the treat-
ment of patients with unresectable, stage III NSCLC whose disease
has not progressed following platinum-based chemoradiotherapy. 3-5
Clinical activity of durvalumab has also been demonstrated in
patients with advanced NSCLC, either alone or in combination
with the anti-cytotoxic T-lymphocyte-associated antigen-4 agent
tremelimumab. 6-8 
The phase 3 MYSTIC study (NCT02453282) was a global,
randomized, open-label trial comparing first-line durvalumab with
or without tremelimumab versus platinum-based chemotherapy
in patients with metastatic NSCLC. 9 MYSTIC did not meet
its primary endpoints of improved OS or PFS with durval-
umab + tremelimumab versus chemotherapy in patients with tumor
cell (TC) PD-L1 expression ≥ 25%. However, durvalumab alone
versus chemotherapy was associated with a numerically reduced risk
of death (hazard ratio [HR] = 0.76; 97.54% confidence interval
[CI], 0.56-1.02; P = .04). 9 
The results from MYSTIC are consistent with those reported
previously for other treatment-naïve, PD-L1 biomarker-selected
trials, including KEYNOTE-042. 10 Based on emerging interest in
tumor mutational burden (TMB) as a biomarker of response, 11
exploratory analyses were conducted for MYSTIC to assess the effect
of TMB, as measured in peripheral blood (bTMB), on outcomes. 9 
In patients with bTMB ≥ 20 mutations per megabase (mut/Mb),
durvalumab + tremelimumab versus chemotherapy was associated
with improved OS (unadjusted HR = 0.49; 95% CI, 0.32-0.74);
whereas, in patients with bTMB < 20 mut/Mb, there was no
observed improvement in OS with durvalumab + tremelimumabClinical Lung Cancer July 2021 versus chemotherapy (unadjusted HR = 1.16; 95% CI, 0.93-1.45).
Among patients with bTMB ≥ 20 mut/Mb who received durval-
umab alone versus chemotherapy, the OS benefit was numerically
greater than the control arm but less marked than with durval-
umab + tremelimumab (unadjusted HR = 0.72; 95% CI, 0.50-
1.05). 
Although improvements in PFS and OS provide robust evidence
for clinical benefit, they are not the only measures of benefit.
Symptom burden in advanced NSCLC is high, with at least 90% of
patients experiencing appetite loss, chest pain, cough, dyspnea, or
fatigue, 12 , 13 which can significantly impact quality of life (QoL). 13
As such, it is increasingly recognized that assessment of new cancer
treatments should extend beyond evaluation of PFS and OS, as
reflected in the value frameworks of several institutions which
take into account other factors besides efficacy and safety, such
as symptom impact and QoL. 14-17 Consequently, it is important
that survival data are supplemented with patient-reported outcomes
(PROs), in order to fully understand the impact of treatment from
the patient’s perspective on symptoms, functioning, and QoL. 18-20 
Here, we report PRO data from MYSTIC in order to assess
the impact of first-line durvalumab with or without tremelimumab
versus chemotherapy on the symptoms, functioning, and global
health status/QoL of patients with metastatic NSCLC. For purposes
of reporting PROs, the population of interest includes patients from
the primary analysis (ie, biomarker-selected patients with PD-L1
TC ≥ 25%). However, PROs for the previously assessed bTMB
populations are also reported. 
Methods 
Patients 
Full inclusion and exclusion criteria have been reported previ-
ously. 9 Briefly, eligible patients were adults with stage IV NSCLC
who had not previously received systemic therapy for advanced or
metastatic NSCLC, had an Eastern Cooperative Oncology Group
performance status score of 0 or 1, had ≥1 measurable lesion accord-
ing to the Response Evaluation Criteria in Solid Tumors version
1.1 (RECIST v1.1), 21 and had known TC PD-L1 expression status































































































prior to randomization. Patients with sensitizing epidermal growth
factor receptor mutations or anaplastic lymphoma kinase rearrange-
ments or who had symptomatic, unstable brain metastases were
excluded. 
The study was conducted in accordance with the International
Conference on Harmonization Good Clinical Practice guidelines
and tenets of the Declaration of Helsinki. The protocol and all
modifications were approved by relevant ethics committees at partic-
ipating centers and regulatory authorities. All patients provided
written informed consent. 
Study Design and Treatment 
MYSTIC (NCT02453282) was a phase 3, multicenter, global,
randomized, open-label study. Patients were randomized 1:1:1 to
receive durvalumab 20 mg/kg every 4 weeks, durvalumab 20 mg/kg
every 4 weeks plus tremelimumab 1 mg/kg every 4 weeks (for up to
four doses), or the investigator’s choice of platinum-based doublet
chemotherapy (four to six cycles). Randomization was stratified
according to PD-L1 TC expression ( ≥25% vs. < 25%) and tumor
histology (squamous vs. non-squamous). Maintenance therapy with
pemetrexed was allowed in patients with non-squamous histology
who had not progressed after four cycles of pemetrexed/platinum
therapy. Crossover from the chemotherapy arm to either of the
durvalumab-containing arms was not allowed. Patients continued
to receive treatment until objective disease progression (per RECIST
v1.1), unacceptable toxicity, or consent withdrawal. 
Endpoints and Assessments 
The primary endpoints were OS (for durvalumab ±
tremelimumab vs. chemotherapy) and PFS (for durval-
umab + tremelimumab vs. chemotherapy), both of which were
assessed in the primary analysis population of patients with
PD-L1 TC ≥ 25%. Secondary endpoints included PFS for the
durvalumab monotherapy arm and objective response rate for
both durvalumab-containing arms, all versus chemotherapy, and
safety, with adverse events (AEs) graded according to the National
Cancer Institute Common Terminology Criteria for AEs (CTCAE)
version 4.03. Patient-reported symptoms, functioning, and global
health status/QoL were assessed as a secondary endpoint using
the European Organisation for Research and Treatment of Cancer
(EORTC) Core Quality of Life 30-item questionnaire (QLQ-C30),
version 3, and its 13-item lung cancer module (QLQ-LC13). 22 , 23 
Patients completed the questionnaires in their native language using
validated translated versions. 
The QLQ-C30 v3 questionnaire includes five multiple-item
functioning scales (cognitive, emotional, physical, role, and
social); three multiple-item symptom scales (fatigue, pain, and
nausea/vomiting); six single-item symptom measures (appetite loss,
constipation, diarrhea, dyspnea, insomnia, and perceived finan-
cial difficulties); and one multiple-item global health status/QoL
scale. 22 The QLQ-LC13 is comprised of one multiple-item dyspnea
scale, single-item measures of other symptoms associated with lung
cancer (cough, hemoptysis, and pain in the arm/shoulder, chest, or
other parts of the body), pain medicine use, side effects of conven-
tional chemotherapy, and, less relevant to this study, radiotherapy
(sore mouth, dysphagia, neuropathy, and hair loss). 23 The analysesreported here focus on symptoms associated with lung cancer and/or
its treatment, as well as health-related QoL (perceived financial diffi-
culties and pain medicine use are not reported). 
Patients completed both questionnaires using a handheld
electronic device. For the QLQ-C30, patients completed the
questionnaire at baseline and at weeks 4 and 8, then every 8 weeks
thereafter until disease progression. For the QLQ-LC13, patients
completed the questionnaire at baseline and at weeks 2, 4, 6, and
8, then every 4 weeks thereafter until disease progression. Patients
who discontinued treatment due to progression had their last PRO
assessment at day 30, post final dose. Patients who discontinued
treatment for reasons other than progression continued to complete
questionnaires until disease progression. Patients who continued to
receive treatment after progression (at the investigator’s discretion
in consultation with the study sponsor) carried on completing the
questionnaires for as long as they remained on treatment. 
Statistical Analysis 
The study was powered for the primary endpoints, as described
previously. 9 The secondary PROs were not part of the main
multiple-testing procedure; therefore, no alpha was allocated for
their analysis, and all reported P values are nominal. However, the
following PRO endpoints were prespecified as primary symptoms of
lung cancer: cough, dyspnea, and chest pain (all QLQ-LC13) and
fatigue and appetite loss (both QLQ-C30). For the mixed model
for repeated measures (MMRM) analyses of these five symptoms, as
described below, the overall type I error (5% 2-sided) was controlled
using a Bonferroni adjusted 1% significance level, and 99% CIs
were reported. In addition, physical functioning and global health
status/QoL (both QLQ-C30) were prespecified as PRO endpoints
of interest. 
Using the same data cutoff as that used for the final OS analysis
(October 4, 2018), PROs were assessed and analyzed, as prespec-
ified, in patients with PD-L1 TC ≥ 25% and, for purposes of
exploratory analyses, in populations defined by a bTMB cutoff of
20 mut/Mb. 
Summary statistics were compiled for overall compliance and
compliance over time for both the QLQ-C30 and QLQ-LC13
questionnaires. In addition, summary statistics were compiled for
all items included in the questionnaires at all assessed time points.
Scores for the QLQ-30 and QLQ-LC13 questionnaires were calcu-
lated according to the published scoring guidelines or developer’s
guidelines. The raw scores from the scales in both questionnaires
were standardized by linear transformation in order to range from
0 to 100 total. Higher scores for symptom items indicate greater
symptom severity; higher scores for function and global health
status/QoL items indicate better function and health status. 19 , 20 
For both questionnaires, a ≥10-point change in score from baseline
(either deterioration or improvement) was predefined as clinically
meaningful. 24 
Mean change from baseline over 12 months was evaluated for
the five prespecified key symptoms (cough, dyspnea, and chest pain
[all QLQ-LC13] and fatigue and appetite loss [both QLQ-C30])
using MMRM analysis. The MMRM model compared the average
treatment effect of PROs from randomization until disease progres-
sion or 12 months (whichever was earlier) accounting for multipleClinical Lung Cancer July 2021 303 
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Figure 1 MMRM-Adjusted Mean Changes from Baseline Over 12 Months in Prespecified Key Symptoms (PD-L1 TC ≥ 25% 
Population). Presented Are Adjusted Mean Changes From Baseline (Bars), and Between-Group Differences ( ) with 
99% CIs and Nominal P Values. A Negative Difference ( ) Favors the Respective Durvalumab Arm Over Chemotherapy. 
A Difference ( ) of ≥10 Was Predefined As Clinically Meaningful. 
Abbreviations: CI = confidence interval; MMRM = mixed model for repeat measures; PD-L1 = programmed cell death 
protein ligand 1; QLQ-C30 = EORTC Core Quality of Life 30-item questionnaire; QLQ-LC13 = EORTC Core Quality of Life 

















































304 visits for each patient. The MMRM analysis included treatment,
age at randomization ( < 65 vs. ≥65 years), sex (male vs. female),
smoking history (smoker vs. non-smoker), visit, and treatment-by-
visit interaction as fixed effects and the baseline score as a covariate;
in addition, the model adjusted for the baseline score-by-visit inter-
action. 
Time to deterioration (TTD) of PROs was assessed in patients
with baseline scores of ≥10 for functioning and global health
status/QoL and ≤90 for symptoms. TTD was defined as the time
from randomization until the date of the first clinically meaning-
ful deterioration ( ≥10-point increase for symptoms; ≥10-point
decrease for functioning items and global health status/QoL), as
confirmed at a subsequent assessment, or death from any cause
in the absence of clinically meaningful deterioration. TTD was
analyzed using a stratified log-rank test, adjusting for histology
(squamous vs. non-squamous), with ties handled using the Breslow
approach; HRs and 95% CIs were estimated by a Cox proportional
hazards model. Median TTD was estimated using the Kaplan–
Meier method. Data underlying the findings described in this
manuscript may be obtained in accordance with AstraZeneca’s




Overall, 1891 patients from 203 sites in 17 countries were
enrolled between July 2015 and June 2016. 9 In total, 1118 patients
were randomized to durvalumab monotherapy ( n = 374), durval-
umab + tremelimumab ( n = 372), or chemotherapy ( n = 372),
comprising the intention-to-treat (ITT) population, of whom 1092Clinical Lung Cancer July 2021 (97.7%) received at least one dose of study treatment ( n = 369, 371,
and 352, respectively). 
The primary analysis population (patients with PD-L1 TC ≥
25%) included 488 patients (43.6% of all randomized patients).
Among 809 bTMB-evaluable patients, 211 patients (26.1%) had
bTMB ≥ 20 mut/Mb and 598 patients (73.9%) had bTMB < 20
mut/Mb. 
As reported previously, baseline demographics and disease charac-
teristics of the primary analysis population (PD-L1 TC ≥ 25%),
the ITT population, and the bTMB populations defined by the 20-
mut/MB cutoff were generally consistent and balanced among the
treatment groups. 9 
As of the data cutoff (October 4, 2018), median follow-up for
OS was 30.2 (range, 0.3-37.1) months. Among patients with PD-
L1 TC ≥ 25%, 44.8% in the durvalumab arm, 37.4% in the
durvalumab + tremelimumab arm, and 58.6% in the chemotherapy
arm had received any subsequent (post-discontinuation) anticancer
therapy; among these patients in the chemotherapy arm, 67% had
received subsequent immunotherapy. 9 
Baseline Scores and Compliance 
Among patients with PD-L1 TC ≥ 25%, there were no clini-
cally relevant between-treatment differences in baseline symptoms,
functioning, or global health status/QoL (Supplemental Table
1 ). However, low baseline scores ( < 10 points) were reported
for diarrhea and nausea/vomiting (both QLQ-C30) and alope-
cia, dysphagia, hemoptysis, peripheral neuropathy, and sore mouth
(all QLQ-LC13), precluding the possibility of reporting clini-
cally meaningful improvements for these endpoints. (A clinically
meaningful improvement required a reduction from baseline of 10
points or more.) Similar baseline scores were observed in the bTMB
Edward B. Garon et al 
Figure 2 Time to Deterioration in Symptoms, Functioning, and Global Health Status/QoL for (A) Durvalumab Versus 
Chemotherapy and (B) Durvalumab + Tremelimumab Versus Chemotherapy (PD-L1 TC ≥ 25% Population). QLQ-C30 
and QLQ-LC13 Symptom Scales/Items Are Based on Patients With Baseline Score ≤ 90. QLQ-C30 Functional Scales 
and Global Health Status/QoL Are Based on Patients With Baseline Scores ≥ 10. A Hazard Ratio < 1.0 Indicates Longer 
TTD With Immunotherapy Versus Chemotherapy. Stratified Log-Rank Test Adjusting for Histology (Squamous vs. 
Non-squamous), With Ties Handled Using the Breslow Approach. 
Abbreviations: CI = confidence interval; PD-L1 = programmed cell death protein ligand 1; QLQ-C30 = EORTC Core 
Quality of Life 30-item questionnaire; QLQ-LC13 = EORTC Core Quality of Life 13-item lung cancer questionnaire; 











≥ 20 mut/Mb and bTMB < 20 mut/Mb populations and the ITT
population (Supplemental Table 2 ). 
In the PD-L1 TC ≥ 25% population, compliance in completing
the QLQ-C30 questionnaire was ≥60% up to week 120 in both
durvalumab-containing arms and up to week 40 in the chemother-
apy arm (Supplemental Figure 1A ). Among these patients, compli-ance for the QLQ-LC13 questionnaire was ≥60% up to week 120
in both durvalumab arms and up to week 44 in the chemotherapy
arm (Supplemental Figure 1B ). In the bTMB-evaluable populations,
compliance for both the QLQ-C30 and QLQ-LC13 questionnaires
was ≥60% up to week 96 in both durvalumab arms and up to week
24 in the chemotherapy arm (data not shown). Clinical Lung Cancer July 2021 305 
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Figure 3 Kaplan–Meier Analysis of Time to Deterioration for (A) Global Health Status/QoL and the Clinically Relevant Symptoms 
of (B) Fatigue, (C) Appetite Loss, (D) Nausea/Vomiting, (E) Diarrhea, (F) Dyspnea, and (G) Cough (PD-L1 TC ≥ 25% 
Population). QLQ-C30/QLQ-LC13 Symptom Scales/Items Are Based on Patients With Baseline Score ≤ 90. QLQ-C30 
Global Health Status/QoL Is Based on Patients With Baseline Score ≥ 10. 
Abbreviations: PD-L1 = programmed cell death protein ligand 1; QLQ-C30 = EORTC Core Quality of Life 30-item 
questionnaire; QLQ-LC13 = EORTC Core Quality of Life 13-item lung cancer questionnaire; QoL = quality of life; 































306 Changes from Baseline 
In the PD-L1 TC ≥ 25% population, the differences in the
MMRM-adjusted mean changes from baseline over 12 months
( Figure 1 ) favored the durvalumab arm versus the chemother-
apy arm for appetite loss (nominal P < .001) and fatigue
(nominal P = .001) (both QLQ-C30). In addition, the between-
group difference for appetite loss was clinically meaningful ( −11.9
points). There was also a difference in the MMRM-adjusted mean
change from baseline that favored durvalumab + tremelimumab
versus chemotherapy for QLQ-C30 fatigue (nominal P < .001),
with the between-group difference being clinically meaningful
( −11.7 points). These differences were largely attributable to
changes in the chemotherapy arm; whereas, in the durvalumab
arms, these symptoms remained stable or decreased in frequency.
For cough, dyspnea, and chest pain (all QLQ-LC13), there
were no differences in the MMRM-adjusted mean changes fromClinical Lung Cancer July 2021 baseline between the durvalumab arms and the chemotherapy arm
( Figure 1 ). 
In both of the bTMB populations ( ≥20 and < 20 mut/Mb),
the MMRM-adjusted mean changes from baseline over 24 weeks
did not favor durvalumab versus chemotherapy for any of the
prespecified key symptoms (Supplemental Figure 2 ). (The MMRM
analyses for the bTMB populations were based on 24 weeks,
not 12 months, due to limited records after 24 weeks in the
chemotherapy arm.) However, among patients with bTMB ≥ 20
mut/Mb, there were differences in the MMRM-adjusted mean
changes from baseline favoring durvalumab + tremelimumab versus
chemotherapy for appetite loss and fatigue (both QLQ-C30 with
nominal P < .001); the between-arm differences were clini-
cally meaningful for both (–17.0 and –17.5, respectively; Supple-
mental Figure 2 ). However, there were no equivalent differ-
ences among patients with bTMB < 20 mut/Mb. The reported
Edward B. Garon et al 










































differences largely reflect a clinically meaningful deterioration in
these symptoms in the chemotherapy arm. There were no differ-
ences between the durvalumab arms and chemotherapy arm in
adjusted mean changes from baseline for cough, dyspnea, or chest
pain (all QLQ-LC13) in either bTMB population (Supplemental
Figure 2 ). 
Based on absolute scores, most PROs remained stable over
time among patients with PD-L1 TC ≥ 25% in the durval-
umab arms, with no clinically meaningful changes from baseline
to week 48 (data not shown), except for the following endpoints
that showed improvement: QLQ-LC13 cough (mean change,
–16.3; SD = 29.9) with durvalumab and QLQ-C30 dyspnea (mean
change, –18.9; SD = 32.0) with durvalumab + tremelimumab. In
contrast, within the chemotherapy arm, there were clinically
meaningful changes from baseline to week 48 for several endpoints,
reflecting either improvement or worsening: emotional functioning
(mean change, 13.9; SD = 17.2), role functioning (mean change,
–11.1; SD = 13.6), appetite loss (mean change, –11.1; SD = 40.4),
constipation (mean change, –11.1; SD = 27.2), dyspnea (mean
change, 11.1; SD = 17.2), and nausea/vomiting (mean change,
11.1; SD = 17.2) (all QLQ-C30); as well as cough (mean change,
–16.7; SD = 35.0), arm/shoulder pain (mean change, –22.2;
SD = 34.4), chest pain (mean change, –11.1; SD = 27.2), otherpain (mean change, –11.1; SD = 27.2), alopecia (mean change,
11.1; SD = 17.2), and peripheral neuropathy (mean change, 22.2;
SD = 34.4) (all QLQ-LC13). There were no clinically meaningful
absolute changes from baseline in global health status/QoL items
across all treatment groups. 
Time to Deterioration 
Among patients with PD-L1 TC ≥ 25%, TTD was longer
with durvalumab versus chemotherapy (nominal P < .01) for
hemoptysis (QLQ-LC13) and appetite loss, constipation, diarrhea,
dyspnea, insomnia, and nausea/vomiting, as well as four function-
ing domains (cognitive, physical, role, and social) and global
health status/QoL (all QLQ-C30) ( Figure 2 A). In addition, TTD
was longer with durvalumab + tremelimumab versus chemother-
apy (nominal P < .01) for appetite loss, constipation, dyspnea,
fatigue, and nausea/vomiting, as well as three functioning domains
(cognitive, physical, and social), and global health status/QoL (all
QLQ-C30) ( Figure 2 B). There were no other differences between
the durvalumab arms and chemotherapy for any other parameters
(based on nominal P values). 
Among patients with bTMB ≥ 20 mut/Mb, TTD was
longer with durvalumab versus chemotherapy for social function-
ing, appetite loss, constipation, and nausea/vomiting (all QLQ-Clinical Lung Cancer July 2021 307 
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Figure 4 Kaplan–Meier Analysis of Time to Deterioration for (A) Global Health Status/QoL and the Clinically Relevant Symptoms 
of (B) Fatigue, (C) Appetite Loss, (D) Nausea/Vomiting, (E) Diarrhea, (F) Dyspnea, and (G) Cough (bTMB ≥ 20 
Population). QLQ-C30 Global Health Status/QoL Is Based on Patients With Baseline Scores ≥ 10. QLQ-C30/QLQ-LC13 
Item/Symptom Scales Are Based on Patients With Baseline Score ≤ 90. 
Abbreviations: bTMB = blood tumor mutational burden; Mb = megabase; mut = mutation; QLQ-C30 = EORTC Core 
Quality of Life 30-item questionnaire; QLQ-LC13 = EORTC Core Quality of Life 13-item lung cancer questionnaire; 































308 C30) and cough (QLQ-LC13) (Supplemental Figure 3A ). In
addition, TTD was longer with durvalumab + tremelimumab
versus chemotherapy for global health status/QoL and all
functioning domains (all QLQ-C30), as well as appetite loss, consti-
pation, fatigue, nausea/vomiting, pain, and insomnia (all QLQ-
C30) and cough, arm or shoulder pain, chest pain, and other pain
(all QLQ-LC13) (Supplemental Figure 3B ). In contrast, among
patients with bTMB < 20 mut/Mb, there were no clinically impor-
tant differences in TTD between the durvalumab-containing arms
and the chemotherapy arm (Supplemental Figures 4A and 4B ), apart
from TTD for nausea/vomiting (QLQ-C30), which was longer
with durvalumab versus chemotherapy, and other pain (QLQ-
LC13), which was longer with chemotherapy than with durval-
umab + tremelimumab. 
Kaplan–Meier analyses of TTD for items considered most
clinically relevant to patients—global health status/QoL, fatigue,
appetite loss, nausea/vomiting, diarrhea, and dyspnea (all QLQ-Clinical Lung Cancer July 2021 C30) and cough (QLQ-LC13)—are presented in Figure 3 (PD-
L1 TC ≥ 25% population), Figure 4 (bTMB ≥ 20 mut/Mb), and
Supplemental Figure 5 (bTMB < 20 mut/Mb). 
Discussion 
Among patients with metastatic NSCLC and PD-L1 TC ≥ 25%
in MYSTIC, first-line durvalumab monotherapy versus chemother-
apy was associated with a numerically reduced risk of death
(HR = 0.76; 97.54% CI, 0.56-1.02; P = .04). 9 In addition, in
an exploratory analysis of patients with bTMB ≥ 20 mut/Mb,
durvalumab + tremelimumab versus chemotherapy was associated
with improved OS (unadjusted HR = 0.49; 95% CI, 0.32-0.74).
The safety profiles of both durvalumab arms were consistent with
data from prior trials, and both arms versus chemotherapy were
associated with fewer grade ≥3 treatment-related AEs. 9 To fully
understand the impact of treatment, here we report, for the first
time, to our knowledge, the impact of first-line durvalumab,
Edward B. Garon et al 










































with or without tremelimumab, on symptoms, functioning, and
global health status/QoL in patients with metastatic NSCLC from
MYSTIC. 
Based on the MMRM analyses, patients with PD-L1 TC ≥
25% who received durvalumab, with or without tremelimumab,
reported clinically meaningful improvements in prespecified key
symptoms of NSCLC and experienced reduced symptom burden
over time, compared with patients who received chemotherapy. In
both of the bTMB populations, the adjusted mean changes from
baseline did not favor durvalumab versus chemotherapy for any
of the key symptoms. In contrast, among patients with bTMB
≥ 20 mut/Mb, there were differences in MMRM-adjusted mean
changes from baseline favoring durvalumab + tremelimumab versus
chemotherapy for appetite loss and fatigue, with no equivalent
differences among patients with bTMB < 20 mut/Mb. For both
the PD-L1 TC ≥ 25% population and patients with bTMB ≥
20 mut/Mb, any differences were largely attributable to changes in
the chemotherapy arm (ie, deterioration in symptoms); whereas, in
the durvalumab-containing arms, these symptoms remained stable
or decreased in frequency (evidence of better tolerability from the
patient’s perspective). 
Patients with PD-L1 TC ≥ 25% who received durvalumab, with
or without tremelimumab, also experienced longer TTD acrossa broad range of symptoms, several functioning domains, and
global health status/QoL, compared with patients who received
chemotherapy. These results illustrate that health-related QoL
appears to be maintained in patients within the durvalumab-
containing arms. Among patients with bTMB ≥ 20 mut/Mb,
TTD was longer with durvalumab versus chemotherapy for appetite
loss, constipation, nausea/vomiting, cough, and social functioning.
In addition, TTD was longer with durvalumab + tremelimumab
versus chemotherapy for global health status/QoL and all function-
ing domains, as well as several symptoms. In contrast, among
patients with bTMB < 20 mut/Mb, TTD did not generally
differ between the durvalumab-containing and chemotherapy arms.
Longer TTD for typical tumor symptoms, such as cough, dyspnea,
and pain, suggests a better efficacy of immunotherapy in the pertain-
ing subsets and treatment groups. 
Overall, these data are consistent with PRO results from
other immunotherapy studies, examining the impact of first-line
monotherapy or combination therapy on symptoms and health-
related QoL in patients with advanced NSCLC. In KEYNOTE-
024, among treatment-naïve patients with stage IV PD-L1-positive
(a tumor proportion score of ≥50%) NSCLC, pembrolizumab
improved or maintained health-related QoL compared with
chemotherapy. 25 In CheckMate-227, treatment-naïve patients withClinical Lung Cancer July 2021 309 





































































































310 stage IV NSCLC and high TMB ( ≥10 mut/Mb) who received
nivolumab + ipilimumab experienced more rapid, durable, and
clinically meaningful improvements in PROs compared with
those assigned to chemotherapy. 26 Our findings also align with
those from studies carried out in previously treated patients
with advanced NSCLC, in which QoL and symptoms were
maintained or improved to a greater degree with pembrolizumab 27
or nivolumab 28 , 29 than with chemotherapy. Similarly, in the OAK
trial, atezolizumab prolonged TTD in physical function and role
function and numerically improved patients’ health-related QoL
from baseline compared with chemotherapy in patients with previ-
ously treated advanced or metastatic NSCLC. 30 Finally, results of
the present analyses also agreed with those from the PACIFIC
study, in which clinical benefit with durvalumab monotherapy
versus placebo was achieved with no detrimental effect on PROs
in patients with stage III, unresectable NSCLC who had received
prior chemoradiotherapy. 31 
Certain limitations of the current analysis should be acknowl-
edged. For example, the MYSTIC study was an open-label trial,
meaning that patients assigned to immunotherapy may have
overestimated improvements; whereas, patients assigned to
chemotherapy may have under-reported improvements, potentially
biasing the results. 32 , 33 On the other hand, at baseline, patients
assigned to receive durvalumab (with or without tremelimumab)
may have overestimated their wellbeing (because they were pleased
to be receiving the investigational product); whereas, those in the
chemotherapy arm may have underestimated their wellbeing (owing
to disappointment). This could have led to an underestimation of
the effects of immunotherapy 32 ; however, a small analysis of PROs
collected in blinded and open-label trials of identical oncology
drugs has found no between-trial differences in compliance rates or
evidence to suggest overestimation of improvements in open-label
trials. 34 In addition, the QLQ-C30 and QLQ-LC13 questionnaires
were developed in the early 1990s in the era of chemotherapy, 22 , 23
which may limit their relevance in immunotherapy settings. For
example, potential symptoms related to immunotherapies (eg,
feeling cold, rash, weight gain or weight loss) 5 are not captured.
Another limitation includes the fact that the sample size in the
chemotherapy arm was markedly lower than in the immunotherapy
arms from week 24 onward, potentially biasing results in favor
of chemotherapy. Importantly, the study was not powered for
secondary endpoints (ie, PROs); thus, these results should be
considered exploratory only, as any observed benefits (which may
appear overstated with results reported for two investigational arms)
are based on nominal P values. Finally, there is no gold-standard
definition for TTD, which may be influenced by the mechanism of
action of a drug, disease stage, treatment line, and cancer type. 
Conclusions 
In summary, these data show that first-line durvalumab, with or
without tremelimumab, versus chemotherapy had a positive impact
on a broad range of PROs, reducing symptom burden and prolong-
ing TTD in metastatic NSCLC patients with PD-L1 TC ≥ 25% or
bTMB ≥ 20 mut/Mb. These findings complement and support the
numerically reduced risk of death observed with first-line durval-
umab versus chemotherapy as previously reported in patients withClinical Lung Cancer July 2021 metastatic NSCLC. In addition, the PRO results suggest that
there are no detrimental effects on QoL with immune checkpoint
inhibitors compared to chemotherapy, which may prove benefi-
cial in future studies of immunotherapy in patients with advanced
NSCLC and high PD-L1 TC expression. 
Clinical Practice Points 
In the phase 3 MYSTIC trial of metastatic NSCLC, the primary
endpoints of improved overall survival or progression-free survival
with first-line durvalumab + tremelimumab versus chemotherapy
were not met in patients with PD-L1 TC expression ≥ 25%.
However, durvalumab alone versus chemotherapy was associated
with a numerically reduced risk of death. 
Symptom burden in advanced NSCLC is high, which can signifi-
cantly impact quality of life. It is, therefore, important to supple-
ment survival data with patient-reported outcomes, in order to
fully understand the impact of treatment on symptoms, function-
ing, and quality of life from the patient’s perspective. 
The present analyses showed that durvalumab ± tremelimumab
reduced symptom burden and improved times to deterioration of
patient-reported outcomes in patients with PD-L1 TC ≥ 25%,
suggesting it had no detrimental effects on quality of life. 
These findings suggest that there are no detrimental effects on
quality of life with immune checkpoint inhibitors, compared to
chemotherapy, which may prove beneficial in future studies of
immunotherapy in patients with advanced NSCLC and high
PD-L1 TC expression. 
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Supplemental Figure 5 Kaplan-Meier Analysis of Time to Deterioration for Global Health Status/QoL (A) and the Clinically 
Relevant Symptoms of Fatigue (B), Appetite Loss (C), Nausea/Vomiting (D), Diarrhea (E), Dyspnea (F), 
and Cough (G) (bTMB < 20 mut/Mb Population) 
QLQ-C30 global health status/QoL is based on patients with baseline scores ≥10. QLQ-C30/QLQ-LC13 
item/symptom scales are based on patients with baseline score ≤90. 
Abbreviations: bTMB = blood tumor mutational burden; Mb = megabase; mut = mutation; 
QLQ −C30 = 30-item core quality of life questionnaire; QLQ-LC13 = 13-item lung cancer module quality of 
life questionnaire; QoL = quality of life. 
Clinical Lung Cancer July 2021 312.e5 





312.e6Supplemental Table 1 Baseline Symptoms, Functioning, and
Durvalumab Monothe
(n = 163) 
QLQ −C30 score, 
mean (SD) 
Appetite loss 27.2 (32.4) 
Constipation 19.5 (28.9) 
Diarrhea 5.7 (14.3) 
Dyspnea 34.2 (31.7) 
Fatigue 36.4 (25.5) 
Insomnia 31.1 (30.1) 
Nausea/vomiting 7.7 (14.2) 










Role functioning 71.4 (29.8) 




QLQ −LC13 score, 
mean (SD) 
Alopecia 4.9 (15.8) 
Cough 43.4 (28.8) 
Dysphagia 7.5 (17.4) 
Dyspnea 26.9 (22.5) 
Hemoptysis 5.1 (13.9) 
Pain in arm or 
shoulder 
15.2 (22.3) 
Pain in chest 18.6 (23.9) 




Sore mouth 6.5 (16.9) 
Shaded cells indicate symptoms for which low ( < 10) baseline values were reported; clinicall
PD-L1 = programmed cell death ligand-1; QLQ −C30 = 30-item core quality of life questionnair
cell.  Clinical Lung Cancer July 2021 al Health Status/QoL (PD-L1 TC ≥25% Population). 
 Durvalumab + Tremelimumab 
(n = 163) 
Chemotherapy 
(n = 162) 
21.3 (28.6) 23.3 (28.3) 
16.9 (28.2) 18.0 (26.7) 
3.9 (12.8) 6.0 (17.6) 
37.0 (29.0) 34.3 (28.1) 
37.3 (24.8) 37.7 (27.9) 
29.6 (28.7) 32.9 (34.1) 
5.2 (10.3) 5.2 (11.3) 
31.9 (29.1) 33.5 (30.3) 
86.1 (19.9) 86.5 (19.2) 
75.2 (22.7) 70.1 (23.4) 
74.0 (22.1) 72.4 (22.5) 
70.0 (30.1) 68.8 (32.0) 
79.9 (25.7) 75.1 (28.5) 
59.3 (19.2) 57.4 (23.0) 
3.5 (13.0) 3.8 (11.4) 
43.0 (26.9) 37.6 (26.7) 
5.4 (14.2) 7.3 (18.0) 
28.0 (22.8) 27.2 (22.2) 
6.6 (14.5) 7.0 (16.4) 
22.2 (31.0) 21.6 (29.6) 
21.5 (26.8) 17.8 (25.1) 
23.6 (27.5) 27.3 (29.3) 
7.3 (17.0) 11.3 (20.9) 
3.1 (9.7) 4.3 (13.2) 
ingful improvements in these symptoms were therefore not possible to determine. Abbreviations: 
LC13 = 13-item lung cancer quality of life questionnaire; SD = standard deviation; TC = tumor 
Edward B. Garon et al 
Supplemental Table 2 Baseline Symptoms, Functioning, and Global Health Status/QoL in the bTMB ≥20 mut/Mb (A) and bTMB 
< 20 mut/Mb (B) Populations. 
Durvalumab Monotherapy 
(n = 77) 
Durvalumab + Tremelimumab 
(n = 64) 
Chemotherapy 
(n = 70) 
(A) bTMB ≥20 mut/Mb 
QLQ −C30 score, 
mean (SD) 
Appetite loss 26.0 (31.1) 27.4 (32.5) 22.4 (27.3) 
Constipation 17.8 (29.4) 16.7 (23.8) 14.6 (25.1) 
Diarrhea 5.5 (19.3) 4.2 (14.3) 7.3 (18.3) 
Dyspnea 36.1 (29.8) 38.1 (31.4) 33.3 (30.3) 
Fatigue 36.5 (26.9) 39.7 (26.9) 33.0 (24.1) 
Insomnia 29.2 (28.8) 29.2 (26.3) 27.1 (31.9) 
Nausea/vomiting 7.5 (14.7) 6.3 (13.3) 5.5 (9.9) 
Pain 31.5 (29.5) 28.3 (28.6) 30.0 (25.2) 
Cognitive 
functioning 
88.8 (16.0) 87.5 (19.1) 89.3 (15.8) 
Emotional 
functioning 
69.5 (21.3) 72.6 (23.1) 78.5 (19.2) 
Physical 
functioning 
75.6 (20.2) 74.8 (23.4) 75.0 (18.9) 
Role functioning 75.1 (27.8) 73.5 (31.6) 71.9 (28.5) 
Social functioning 79.9 (26.5) 80.1 (26.9) 80.5 (24.0) 
Global health 
status/QoL 
58.7 (24.2) 61.6 (20.3) 60.9 (21.3) 
QLQ −LC13 score, 
mean (SD) 
Alopecia 3.3 (10.0) 4.3 (17.2) 6.7 (16.0) 
Cough 43.7 (27.9) 43.8 (27.3) 34.4 (26.0) 
Dysphagia 7.5 (18.9) 4.3 (13.0) 9.4 (21.3) 
Dyspnea 26.9 (22.7) 28.8 (24.4) 25.4 (21.0) 
Hemoptysis 7.5 (16.1) 8.0 (17.1) 5.0 (12.0) 
Pain in arm or 
shoulder 
18.8 (26.3) 19.1 (25.6) 21.7 (28.1) 
Pain in chest 16.0 (23.8) 18.5 (25.6) 20.0 (25.5) 
Pain in other parts 21.1 (28.9) 22.8 (26.6) 18.3 (24.9) 
Peripheral 
neuropathy 
8.9 (20.3) 6.8 (13.6) 7.8 (18.8) 
Sore mouth 6.1 (18.9) 3.1 (9.8) 3.3 (10.1) 
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rapy Durvalumab + Tremelimumab 
(n = 64) 
Chemotherapy 
(n = 70) 
27.3 (31.1) 27.7 (31.2) 
19.1 (30.3) 15.3 (25.8) 
4.6 (14.4) 6.4 (18.1) 
35.8 (31.1) 32.3 (28.7) 
40.2 (25.5) 36.1 (27.4) 
35.4 (30.5) 31.1 (31.9) 
8.1 (15.4) 6.7 (13.5) 
37.3 (30.4) 32.2 (30.5) 
82.8 (21.2) 85.4 (19.4) 
69.8 (24.2) 68.9 (24.5) 
71.3 (22.0) 73.5 (22.9) 
68.2 (29.6) 68.3 (32.0) 
73.6 (28.1) 75.1 (29.1) 
56.3 (21.6) 59.9 (23.1) 
5.3 (16.4) 2.2 (9.1) 
41.8 (28.8) 39.4 (25.7) 
6.9 (15.3) 6.9 (16.5) 
29.8 (24.0) 28.3 (22.5) 
5.3 (13.3) 6.9 (17.7) 
25.9 (31.1) 18.4 (28.5) 
23.9 (26.0) 20.6 (25.9) 
28.6 (31.7) 28.6 (29.1) 
7.7 (16.6) 9.1 (18.4) 
4.1 (14.1) 4.3 (15.1) 
y meaningful improvements in these symptoms were therefore not possible to determine. Abbreviations: 
m core quality of life questionnaire; QLQ −LC13 = 13-item lung cancer quality of life questionnaire; 
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(n = 77) 
(B) bTMB < 20 mut/Mb 
QLQ −C30 score, 
mean (SD) 
Appetite loss 30.2 (33.3) 
Constipation 21.2 (28.1) 
Diarrhea 6.8 (16.0) 
Dyspnea 36.8 (32.9) 
Fatigue 38.3 (27.5) 
Insomnia 34.1 (31.4) 
Nausea/vomiting 7.7 (14.5) 










Role functioning 66.3 (32.6) 




QLQ −LC13 score, 
mean (SD) 
Alopecia 5.3 (18.1) 
Cough 37.9 (28.7) 
Dysphagia 7.2 (16.3) 
Dyspnea 27.9 (23.5) 
Hemoptysis 5.0 (14.8) 
Pain in arm or 
shoulder 
19.8 (26.5) 
Pain in chest 25.3 (26.3) 




Sore mouth 5.5 (14.8) 
Shaded cells indicate symptoms for which low ( < 10) baseline values were reported; clinicall
bTMB = blood tumor mutational burden; Mb = megabase; mut = mutation; QLQ −C30 = 30-ite
SD = standard deviation.  Clinical Lung Cancer July 2021 
